Market Currents
Genentech, a member of the Roche Group (RHHBY.PK), gives updated survival results from Phase III...
-
Friday, December 7, 2012, 7:30 PM ETGenentech, a member of the Roche Group (RHHBY.PK), gives updated survival results from Phase III studies showing that using Perjeta in combination with Herceptin and docetaxel chemotherapy significantly extended the overall survival of people with previously untreated HER2-positive metastatic breast cancer, and that the risk of death was reduced by 34%.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
